Panacea Biotec Ltd. benchmarking: Performance to industry peers

Financial

	Panacea Biotec	Unichem Lab	Gufic Biosciences
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	6.0 .	41.0 .	n/a
R&D as a % of Total Sales	9.86 %	5.35 %	1.28 %
Financials
5 yr Average ROE	37.52 %	1.64 %	16.89 %
5yr average Equity Multiplier	0.36	1.32	2.16
5yr Average Asset Turnover Ratio	0.41	0.47	0.75
5yr Avg Net Profit Margin	26.1 %	-1.68 %	10.24 %
Price to Book	3.14	1.07	4.57
P/E	0.0	8.82	57.61
5yr Avg Cash Conversion Cycle	-170.26 Days	88.84 Days	-15.25 Days
Inventory Days	120.03 Days	151.32 Days	71.73 Days
Days Receivable	42.2 Days	122.86 Days	106.89 Days
Days Payable	325.14 Days	205.05 Days	179.29 Days
5yr Average Interest Coverage Ratio	2.7	2.41	8.9
5yr Avg ROCE	-2.79 %	1.04 %	17.89 %
5yr Avg Operating Profit Margin	-3.85 %	5.43 %	18.12 %
5 yr average Debt to Equity	-0.69	0.11	0.67
5yr CAGR Net Profit	-43.68 %	32.0 %	-2.66 %
5yr Average Return on Assets	9.32 %	-0.65 %	7.7 %
Shareholdings
Promoter Holding	72.48 %	70.22 %	72.5 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-1.11 %	19.29 %	-2.5 %
Change in Mutual Fund Holding (3 Yrs)	0.0	2.38 %	2.6 %

Business

	Panacea Biotec	Unichem Lab	Gufic Biosciences
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Anti - Diabetes 43.91 Gastro Intestinal 13.47 Pain Management 12.87 Anti-Neoplastics 8.18 Vitamins / Minerals / Nutrients 6.09 Respiratory Systems 5.39 Vaccines 5.39 Blood Related 2.99 Hormones 0.6 Others 1.11	-	-
Product Wise Break-Up	Product Wise Break-Up Vaccines 60.08 Formulations 39.92 Research and Development 0 Bulk Drugs and chemicals 0 API 0 Muscle Relaxants 0 Cardiovascular 0 Proton pump inhibitors 0 Anti-fungals 0 Anti-bacterials 0 International 0 CMO 0 Domestic 0	Product Wise Break-Up Bulk Chemicals 7.7 Formulations 92.3 CMO 0 Domestic 0 International 0 Muscle Relaxants 0 Cardiovascular 0 Research and Development 0 Anti-fungals 0 Proton pump inhibitors 0 API 0 Vaccines 0 Anti-bacterials 0	Product Wise Break-Up Bulk Drugs and chemicals 0 Formulations 0 CMO 30.0 Domestic Pharmaceuticals 50.0 International 15.0 Muscle Relaxants 0 Cardiovascular 0 Research and Development 0 Anti-fungals 0 Proton pump inhibitors 0 Active Pharmaceutical Ingredient (API) 5.0 Vaccines 0 Anti-bacterials 0
Location Wise Break-Up	Location Wise Break-Up Rest of the World 86.09 India 13.91 USA 0 South America 0 Australia 0 North America 0 Europe 0 Asia 0 Africa 0	Location Wise Break-Up Rest of the World 0 USA 64.2 Australia 0 South America 0 Africa 0 India 1.97 North America 0 Europe 0 Asia 0 Others 33.83	Location Wise Break-Up Rest of the World 0 USA 0 Australia 0.08 South America 2.37 Africa 2.95 India 79.83 North America 1.19 Europe 7.54 Asia Pacific 6.04
Operating Profit Break-Up	Operating Profit Break-Up Others 100	-	-
Capex	Capex Vaccines 69.46 Formulations 30.54 Real estate 0	-	-
Brand Wise Break-Up	Brand Wise Break-Up PanGraf 21.0 Glizid Family 19.0 Sitcom Family 10.0 Mycept & Mycept 5.0 Livoluk Family 4.0 Panimun Bioral 4.0 PacliAll 1.0 Thank OD Family 0 Nimulid Family 0 Others 36.0	-	-
Asset Break-Up	Asset Break-Up Vaccines 68.98 Formulations 31.02 Real Estate 0	-	-

Panacea Biotec Ltd.

Panacea Biotec Ltd.

Financial

Business

SIGN UP FOR FREE